Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR.

Sci Rep. 2015 Aug 24;5:13179. doi: 10.1038/srep13179.

2.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH.

HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27.

PMID:
26212575
3.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410. eCollection 2015.

4.

Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.

Fisher RG, Smith DM, Murrell B, Slabbert R, Kirby BM, Edson C, Cotton MF, Haubrich RH, Kosakovsky Pond SL, Van Zyl GU.

J Clin Virol. 2015 Jan;62:48-53. doi: 10.1016/j.jcv.2014.11.014. Epub 2014 Nov 20.

PMID:
25542470
5.

Antiretroviral therapy in the elite controller: justified or premature?

Karris MY, Haubrich RH.

J Infect Dis. 2015 Jun 1;211(11):1689-91. doi: 10.1093/infdis/jiu812. Epub 2014 Dec 15. No abstract available.

PMID:
25512628
6.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

7.

Will risk compensation accompany pre-exposure prophylaxis for HIV?

Blumenthal J, Haubrich RH.

Virtual Mentor. 2014 Nov 1;16(11):909-15. doi: 10.1001/virtualmentor.2014.16.11.stas1-1411. No abstract available.

8.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

9.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, Moore RD, Haubrich RH, Gopal S, Eron JJ, Hunt PW, Rodriguez B, Mayer K, Saag MS, Kitahata MM; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS).

Clin Infect Dis. 2014 Jun;58(11):1599-606. doi: 10.1093/cid/ciu076. Epub 2014 Feb 12.

10.

Community HIV-1 drug resistance is associated with transmitted drug resistance.

Tilghman MW, Pérez-Santiago J, Osorio G, Little SJ, Richman DD, Mathews WC, Haubrich RH, Smith DM.

HIV Med. 2014 Jul;15(6):339-46. doi: 10.1111/hiv.12122. Epub 2014 Jan 12.

11.

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

Huang JS, Hughes MD, Riddler SA, Haubrich RH; Aids Clinical Trials Group A5142 Study Team.

HIV Clin Trials. 2013 Sep-Oct;14(5):224-34. doi: 10.1310/hct1405-224.

12.

Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.

Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM.

J Infect Dis. 2014 Feb 1;209(3):452-6. doi: 10.1093/infdis/jit434. Epub 2013 Aug 20.

13.

Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.

Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang F, Ginocchio CC, Haubrich RH, Morris SR; CCTG 592 Team.

Clin Infect Dis. 2013 Aug;57(3):441-7. doi: 10.1093/cid/cit252. Epub 2013 Apr 17.

14.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams.

AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20.

15.

Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.

Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH.

PLoS One. 2011;6(6):e21189. doi: 10.1371/journal.pone.0021189. Epub 2011 Jun 20.

16.

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data.

Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, Haubrich RH.

Cost Eff Resour Alloc. 2011 May 8;9:5. doi: 10.1186/1478-7547-9-5.

17.

Defining treatment failure in resource-rich settings.

Aldous JL, Haubrich RH.

Curr Opin HIV AIDS. 2009 Nov;4(6):459-66. doi: 10.1097/COH.0b013e328331dea5. Review.

18.

The use of pooled viral load testing to identify antiretroviral treatment failure.

Smith DM, May SJ, Pérez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, Richman DD, Benson CA, Little SJ.

AIDS. 2009 Oct 23;23(16):2151-8. doi: 10.1097/QAD.0b013e3283313ca9.

19.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team.

AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.

20.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk